Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
alirocumab
3
×
amgen
biotech
boston blog main
evolocumab
inclisiran
3
×
life sciences
national blog main
new york blog main
new york top stories
regeneron pharmaceuticals
alnylam pharmaceuticals
boston top stories
clinical trials
heart attack
medicines co.
national top stories
new york
pcsk9
pcsk9 inhibitors
rna interference
sanofi
stroke
boulder/denver blog main
boulder/denver top stories
cardiac
cardiovascular
cause of death
cedar-sinai
cholesterol
circulation
clinical studies
david maron
deals
detroit blog main
detroit top stories
drugs
esperion pharmaceuticals
evercore isi
fda
What
cholesterol
drug
new
lowering
medco
medicines
wave
acquire
agreed
alnylam
based
billion
brings
cash
company
compound
data
deal
drugs
evidence
expensive
faces
fda
financial
foe
healthcare
heart
hint
inhibitors
known
lasting
long
looms
novartis
partner
pcsk
pharmaceuticals
poised
presented
ready
Language
unset
Current search:
inclisiran
×
alirocumab
×
@xconomy.com
4 years ago
Novartis to Acquire MedCo and FDA-Ready Cholesterol Drug for $9.7B
@xconomy.com
5 years ago
New PCSK9 Cholesterol Drug Faces Tough Foe. (Hint: Not Cholesterol.)
@xconomy.com
5 years ago
MedCo Touts New Data for Long-Lasting Heart Drug as Reckoning Looms